成人院外心脏骤停:骨内通路与静脉通路的贝叶斯二次分析(PARAMEDIC-3试验)
这是PARAMEDIC-3随机对照试验的预先设定的贝叶斯二次分析,纳入6082例需建立血管通路的成人院外心脏骤停患者,比较骨内优先与静脉优先策略。使用无信息先验并校正关键基线特征后,骨内优先策略改善30天生存(OR>1.0)的后验概率为18.4%,劣于静脉优先(OR<1.0)的概率为81.6%,但中等效应(OR<0.75)的概率仅13.4%。自主循环恢复方面,骨内优先劣于静脉优先的概率达98.0%。结论认为骨内优先策略更可能有害而非有益,但整体效应可能不大。
要点
- 成人院外心脏骤停需建立血管通路时,骨内优先策略改善30天生存的后验概率仅18.4%,不推荐常规首选骨内通路。
- 骨内优先策略劣于静脉优先策略的后验概率:任何效应(OR<1.0)为81.6%,中等效应(OR<0.75)为13.4%。
- 自主循环恢复(ROSC)方面,骨内优先劣于静脉优先的后验概率高达98.0%,床旁应优先尝试静脉通路。
- 骨内优先产生中等或较大治疗效应的概率低,提示即使有害,整体效应也可能不大,无需绝对禁用。
- 该分析为贝叶斯二次分析,使用无信息先验,结果需结合PARAMEDIC-3主要结果解读。
适用人群与场景
- 成人院外心脏骤停且需要建立血管通路的患者(PARAMEDIC-3纳入标准)。
- 排除人群及具体纳入/排除标准原文未提及。
- 场景为院前急救,非急诊科或ICU内。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值。
- 策略比较为骨内优先与静脉优先建立血管通路,但具体操作流程原文未提及。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:PARAMEDIC-3随机对照试验的预先设定贝叶斯二次分析,样本量6082例,多中心(具体中心数原文未提及)。
- 人群:成人院外心脏骤停需血管通路者;干预:骨内优先策略;对照:静脉优先策略。
- 主要终点30天生存:骨内优先改善的后验概率18.4%(OR>1.0),劣于静脉优先的概率81.6%(OR<1.0)。
- 骨内优先劣于静脉优先的概率:小效应(OR<0.9)为55.0%,中等效应(OR<0.75)为13.4%。
- favorable神经功能结局:结果与30天生存相当(具体数值原文未提及)。
- ROSC:骨内优先劣于静脉优先(OR<1.0)的后验概率98.0%。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:随机对照试验的贝叶斯二次分析。
- 证据等级或推荐强度:原文未提及。
- 局限:使用无信息先验(代表最小先验知识);为二次分析;具体单中心/多中心、盲法等设计细节原文未提及。
对床旁实践的改变
- 成人院外心脏骤停建立血管通路时,该分析支持静脉优先策略,不推荐常规骨内优先。
- 骨内优先改善生存概率低(18.4%),且ROSC劣于静脉优先概率高(98.0%),床旁应优先尝试静脉通路。
- 中等或大效应概率低(13.4%),提示整体效应可能不大,临床决策需结合具体情况。
- 适用人群为成人院外心脏骤停需血管通路者;不适用人群及院内场景原文未提及。
指南或共识出处
- PARAMEDIC-3随机对照试验(ISRCTN14223494)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the clinical-effectiveness of an intraosseous-first strategy compared with an intravenous-first strategy in adult out-of-hospital cardiac arrest in a pre-planned Bayesian secondary analysis of the PARAMEDIC-3 trial.
METHODS: In PARAMEDIC-3, adults with out-of-hospital cardiac arrest requiring vascular access were randomised to either an intraosseous-first strategy or an intravenous-first strategy. In this analysis, we describe the probability that an intraosseous-first strategy was superior or inferior to an intravenous-first strategy, and the probability that this exceeds specific odds ratio thresholds. Our outcomes were 30-day survival (primary), favourable neurological outcome at hospital discharge and return of spontaneous circulation at hospital handover. Our primary analysis used non-informative priors, adjusted for key baseline characteristics.
RESULTS: In 6082 randomised participants, the posterior probability that an intraosseous-first strategy improved 30-day survival (odds ratio (OR) > 1.0) was 18.4%. The probability that an intraosseous-first strategy was inferior to an intravenous-first strategy was 81.6% for any effect (OR < 1.0), 55.0% for a small effect (OR < 0.9), and 13.4% for a moderate effect (OR < 0.75). For favourable neurological outcome, findings were comparable to 30-day survival. For return of spontaneous circulation, the posterior probability that an intraosseous-first strategy was inferior to an intravenous-first strategy (OR < 1.0) was 98.0%.
CONCLUSION: Based on non-informative priors, which represent minimal prior knowledge of the treatment effect, an intraosseous-first strategy in adult out-of-hospital cardiac arrest is more likely to be harmful, rather than beneficial. However, the low probability of a moderate or large treatment effect suggests that the overall treatment effect is likely to be modest.
TRIAL REGISTRATION: ISRCTN14223494.
参考来源
- Couper K, Ji C, Deakin CD, et al. Intraosseous versus intravenous access in adult out-of-hospital cardiac arrest: a Bayesian secondary analysis of the PARAMEDIC-3 randomised controlled trial. Resuscitation. 2026. PMID: 42790855. doi:10.1016/j.resuscitation.2026.111335
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。